ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION bulk active fine chemical sources

Subscribe to access the full database, or Get Started Free
Vendor	Vendor Homepage	Vendor Sku	API Url
RR Scientific	⤷ Get Started Free	R6214419	⤷ Get Started Free
>Vendor	>Vendor Homepage	>Vendor Sku	>API Url

Last updated: August 9, 2025

Introduction

Allegra-D 12 Hour is a popular over-the-counter medication prescribed for allergy relief and nasal congestion. Its efficacy hinges on the quality and origin of its active pharmaceutical ingredients (APIs). The primary APIs in Allegra-D 12 Hour are Fexofenadine Hydrochloride, an antihistamine, and Pseudoephedrine Hydrochloride, a decongestant. Ensuring high-purity APIs from reputable sources is critical for formulation integrity, regulatory compliance, and patient safety. This analysis provides an overview of global API sources for these compounds, focusing on supply chain dynamics, manufacturing standards, and sourcing trends.

1. API Components in Allegra-D 12 Hour

Fexofenadine Hydrochloride:
A second-generation antihistamine developed to provide non-sedating allergy relief, with minimal central nervous system penetration. Its chemical structure demands stringent quality controls due to its complex synthesis process.

Pseudoephedrine Hydrochloride:
A sympathomimetic amine that constricts blood vessels to reduce nasal congestion. It originates from natural plant alkaloids or through chemical synthesis, and stricter regulations govern its precursor status.

2. Global API Manufacturing Landscape

2.1 Key Manufacturers of Fexofenadine Hydrochloride

Major pharmaceutical manufacturers supply high-quality Fexofenadine APIs globally, with notable presence in Asia, Europe, and North America:

China — Dominant producer of bulk APIs, including Fexofenadine, due to cost advantages and established chemical manufacturing infrastructure. Leading companies such as Zhejiang Huahai Pharmaceutical and Zhejiang Hisun Pharmaceuticals export batches compliant with international standards (e.g., USP, EP).
India — Hosts several API manufacturers like Aurobindo Pharma and Cadila Healthcare, offering cost-effective, GMP-certified APIs. India’s regulatory landscape (DCGI) mandates compliance with global standards, making Indian APIs increasingly reputable.
Europe — Companies like Evonik and Staay Pharma supply Fexofenadine APIs that meet strict European Pharmacopoeia standards, although they generally cater to niche markets due to higher manufacturing costs.
United States — While most APIs in the US are domestically produced or imported from Asia and Europe, some manufacturers like Amneal produce Fexofenadine API under strict FDA regulations, ensuring high quality for domestic distribution.

2.2 Principal Producers of Pseudoephedrine Hydrochloride

Given its status as a controlled precursor in many jurisdictions, sourcing Pseudoephedrine requires compliance with regulatory frameworks such as:

Chinese Suppliers — Key producers include Zhejiang Hisun Pharmaceuticals and Jiangsu Hengrui Medicine, which supply bulk Pseudoephedrine compliant with international standards.
Indian Vendors — Renowned companies such as Gujarat Ambuja Exports and Shree Krishna Chemicals are recognized for their compliant Pseudoephedrine manufacturing processes, often exporting to pharmaceutical firms worldwide.
European and North American Sources — Fewer in number due to stringent regulations; some licensed manufacturers like Siegfried API produce compliant pseudoephedrine salts for regulated markets.

Note: Due to regulatory restrictions on pseudoephedrine, bulk procurement involves strict documentation, serialization, and licensing procedures across all regions.

3. Quality and Regulatory Standards

GMP Compliance:
APIs for Allegra-D must adhere to Good Manufacturing Practice (GMP) standards mandated by global regulators (FDA, EMA, PMDA). Both Chinese and Indian API producers have invested heavily in GMP compliance to meet pharmaceutical requirements.

Certifications & Quality Control:
Certifications such as USP, EP, and JP ensure API purity standards. Suppliers often provide comprehensive analytical reports, certificates of analysis (CoA), and stability data. Companies with IS0 9001 certification further demonstrate quality management systems.

Regulatory Transparency:
In recent years, API suppliers operating in China and India have improved transparency, with some established companies publishing batch-specific documentation openly. Regulatory agencies increasingly scrutinize supply chains for potential contamination or substandard manufacturing.

4. Supply Chain Dynamics and Trends

4.1 Supply Concentration & Resilience

The bulk API supply chain for Allegra-D is primarily concentrated in Asia, notably China and India. While cost-effective, this concentration raises concerns about supply resilience amid geopolitical tensions, trade restrictions, and pandemics (COVID-19). Diversification strategies are becoming prevalent among pharmaceutical companies.

4.2 Political and Regulatory Impact

The US and European authorities have tightened controls over pseudoephedrine imports due to its role as a precursor for illicit methamphetamine production. Consequently, sources often require licensing and traceability, potentially impacting lead times and costs.

4.3 Cost Dynamics and Market Trends

API prices have fluctuated dramatically, driven by raw material costs, environmental regulations, and manufacturing capacity constraints. Indian and Chinese APIs remain competitive globally, but rising quality standards and border tariffs could influence procurement strategies.

5. Key Considerations for Pharmaceutical Companies

Supplier Due Diligence:
Due to strict regulatory expectations, thorough vetting of API manufacturers is essential. This includes inspection reports, audit history, and compliance certifications.
Supply Chain Security:
Diversify sourcing channels and establish long-term partnerships with multiple approved manufacturers to mitigate risks associated with regulatory crackdowns or natural disruptions.
Cost vs. Quality Balance:
While China and India offer cost advantages, compliance with international quality standards is paramount. High-quality APIs may command higher prices but reduce regulatory and patient safety risks.
Regulatory Documentation:
Ensure API suppliers provide necessary documentation, including Certificates of Analysis, Material Safety Data Sheets, and compliance certifications compatible with import jurisdictions.

Conclusion

The bulk sourcing landscape for the APIs in Allegra-D 12 Hour underscores a global, predominantly Asian-centric supply chain, with China and India being the cornerstones. While cost efficiency remains attractive, rigorous supplier qualification and adherence to regulatory standards are critical. As demand grows and regulatory scrutiny intensifies, diversification and enhanced oversight of API origins will be crucial for maintaining supply chain resilience and ensuring product quality.

Key Takeaways

Dominant Source Countries: China and India supply the majority of Fexofenadine and Pseudoephedrine APIs, respectively, driven by cost and manufacturing capacity.
Regulatory Environment: Stricter controls on pseudoephedrine production and distribution influence sourcing strategies and require thorough licensing and compliance measures.
Quality Assurance: GMP certification and compliance with USP/EP standards are non-negotiable for API procurement, impacting formulation safety and regulatory approval.
Supply Chain Risks: Over-reliance on Asian API sources presents vulnerabilities; diversification and supplier audit programs are essential.
Future Trends: Increasing emphasis on transparency, quality, and regulatory compliance will shape API sourcing strategies, potentially raising costs but ensuring patient safety and market stability.

FAQs

1. What are the primary challenges in sourcing APIs for Allegra-D?
Challenges include navigating regulatory restrictions on pseudoephedrine, ensuring supplier compliance with GMP standards, managing supply chain disruptions, and balancing cost with quality.

2. How does regulatory oversight impact API sourcing globally?
Regulations require strict licensing, documentation, and traceability, especially for pseudoephedrine, leading to complex procurement processes and potential delays.

3. Are there domestic (non-Asian) API sources for Allegra-D?
Limited domestic sources exist; most high-quality APIs are imported from China and India due to their scale and cost advantages. Some US and European companies produce APIs compliant with local standards.

4. How can pharmaceutical companies mitigate risks associated with bulk API sourcing?
Through supplier qualification, diversifying the supplier base, establishing long-term contracts, and conducting regular audits to ensure compliance and resilience.

5. Is the API quality in Chinese and Indian manufacturers comparable to that in Europe and North America?
Yes, many Chinese and Indian manufacturers now operate under strict GMP standards and hold certifications aligning with international quality benchmarks, though due diligence remains essential.

References

[1] U.S. Pharmacopeia (USP). General Chapters & Monographs on API Quality Standards.
[2] European Pharmacopoeia (EP). API standards and specifications.
[3] Industry reports on global API manufacturing and supply chain dynamics, 2022.
[4] Regulatory policies on pseudoephedrine and precursor control measures, DEA and EMCDDA publications.
[5] Company disclosures and certifications from Zhejiang Huahai Pharmaceutical, Aurobindo Pharma, and others.

This comprehensive analysis aims to inform stakeholders involved in pharmaceutical formulation, procurement, and regulatory compliance regarding Allegra-D API sourcing strategies.

Bulk Pharmaceutical API Sources for ALLEGRA-D 12 HOUR ALLERGY AND CONGESTION